According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Cefuroxime Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 2.5
 28.09.2024
 10846471-00007
 Date of first issue: 06.09.2022

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier

Trade name : Cefuroxime Formulation

Other means of identification : Spectrazol Milking Cow (A005270)

Coopers Cepravin LC Lactating Cow Intramammary Antibiotic

(47941)

1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Sub- : Veterinary product

stance/Mixture

Recommended restrictions

on use

Not applicable

1.3 Details of the supplier of the safety data sheet

Company : MSD

Walton Manor, Walton

MK7 7AJ Milton Keynes - United Kingdom

Telephone : +1-908-740-4000

E-mail address of person

responsible for the SDS

: EHSDATASTEWARD@msd.com

1.4 Emergency telephone number

+1-908-423-6000

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Classification (REGULATION (EC) No 1272/2008) as amended by GB-CLP Regulation, UK SI 2019/720, and UK SI 2020/1567)

Respiratory sensitisation, Category 1 H334: May cause allergy or asthma symptoms or

breathing difficulties if inhaled.

2.2 Label elements

Labelling (REGULATION (EC) No 1272/2008) as amended by GB-CLP Regulation, UK SI 2019/720, and UK SI 2020/1567)

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Cefuroxime Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 2.5 28.09.2024 10846471-00007 Date of first issue: 06.09.2022

Hazard pictograms :

Signal word : Danger

Hazard statements : H334 May cause allergy or asthma symptoms or breath-

ing difficulties if inhaled.

Precautionary statements : Response:

P304 + P340 IF INHALED: Remove person to fresh air and

keep comfortable for breathing.

P342 + P311 If experiencing respiratory symptoms: Call a

POISON CENTER/ doctor.

Hazardous components which must be listed on the label:

Cefuroxime

The following percentage of the mixture consists of ingredient(s) with unknown hazards to the aquatic environment: $8.33\,\%$

2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

Components

Chemical name	CAS-No. EC-No. Index-No.	Classification	Concentration (% w/w)
Cefuroxime	55268-75-2 259-560-1	Resp. Sens. 1; H334 STOT RE 2; H373	>= 1 - < 10

For explanation of abbreviations see section 16.

SECTION 4: First aid measures

4.1 Description of first aid measures

General advice : In the case of accident or if you feel unwell, seek medical ad-

vice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

Protection of first-aiders : First Aid responders should pay attention to self-protection,

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Cefuroxime Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 2.5 28.09.2024 10846471-00007 Date of first issue: 06.09.2022

and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

If inhaled : If inhaled, remove to fresh air.

If not breathing, give artificial respiration. If breathing is difficult, give oxygen.

Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty

of water.

Get medical attention if symptoms occur.

In case of eye contact : Flush eyes with water as a precaution.

Get medical attention if irritation develops and persists.

If swallowed, DO NOT induce vomiting.

Get medical attention if symptoms occur. Rinse mouth thoroughly with water.

4.2 Most important symptoms and effects, both acute and delayed

Risks : May cause allergy or asthma symptoms or breathing difficul-

ties if inhaled.

Excessive exposure may aggravate preexisting asthma and other respiratory disorders (e.g. emphysema, bronchitis, reac-

tive airways dysfunction syndrome).

4.3 Indication of any immediate medical attention and special treatment needed

Treatment : Treat symptomatically and supportively.

SECTION 5: Firefighting measures

5.1 Extinguishing media

Suitable extinguishing media : Water spray

Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical

Unsuitable extinguishing

media

None known.

5.2 Special hazards arising from the substance or mixture

Specific hazards during fire-

fighting

Exposure to combustion products may be a hazard to health.

Hazardous combustion prod: :

ucts

Carbon oxides
Nitrogen oxides (NOx)

Sulphur oxides

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Cefuroxime Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 2.5 28.09.2024 10846471-00007 Date of first issue: 06.09.2022

5.3 Advice for firefighters

Special protective equipment :

for firefighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment. Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

SO.

Evacuate area.

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions : Use personal protective equipment.

Follow safe handling advice (see section 7) and personal pro-

tective equipment recommendations (see section 8).

6.2 Environmental precautions

Environmental precautions : Avoid release to the environment.

Prevent further leakage or spillage if safe to do so.

Prevent spreading over a wide area (e.g. by containment or oil

barriers).

Retain and dispose of contaminated wash water.

If spillage enters rivers or watercourses, inform the Environment Agency (emergency telephone number 0800 807060).

6.3 Methods and material for containment and cleaning up

Methods for cleaning up : Soak up with inert absorbent material.

For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absor-

bent.

Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to deter-

mine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

Technical measures : See Engineering measures under EXPOSURE

CONTROLS/PERSONAL PROTECTION section.

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Cefuroxime Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 2.5 28.09.2024 10846471-00007 Date of first issue: 06.09.2022

Local/Total ventilation Use only with adequate ventilation.

Advice on safe handling Do not breathe mist or vapours. Do not swallow.

Avoid contact with eyes.

Avoid prolonged or repeated contact with skin.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure as-

sessment

Keep container tightly closed.

Already sensitised individuals, and those susceptible

to asthma, allergies, chronic or recurrent respiratory disease, should consult their physician regarding working with respira-

tory irritants or sensitisers.

Take care to prevent spills, waste and minimize release to the

environment.

If exposure to chemical is likely during typical use, provide eye Hygiene measures

> flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contami-

nated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the

use of administrative controls.

7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers

Keep in properly labelled containers. Keep tightly closed. Store in accordance with the particular national regulations.

Advice on common storage Do not store with the following product types:

Strong oxidizing agents

Gases

7.3 Specific end use(s)

Specific use(s) No data available

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

Occupational Exposure Limits

Components	CAS-No.	Value type (Form	Control parameters	Basis
		of exposure)		
Cefuroxime	55268-75-2	TWA	100 μg/m3 (OEB 2)	Internal
	Further information: RSEN			

Predicted No Effect Concentration (PNEC)

Substance name	Environmental Compartment	Value
Glycerides, mixed C8-10 and	Fresh water	0.0017 mg/l
succinyl		

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Cefuroxime Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 2.5 28.09.2024 10846471-00007 Date of first issue: 06.09.2022

Freshwater - intermittent	0.676 mg/l
Marine water	0.00017 mg/l
Sewage treatment plant	4.55 mg/kg dry weight (d.w.)
Fresh water sediment	390.49 mg/kg dry weight (d.w.)
Marine sediment	39.05 mg/kg dry weight (d.w.)
Soil	78.01 mg/kg dry weight (d.w.)

8.2 Exposure controls

Engineering measures

Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections).

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Laboratory operations do not require special containment.

Personal protective equipment

Eye/face protection : Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions,

mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

aerosols.

Hand protection

Material : Chemical-resistant gloves

Skin and body protection : Work uniform or laboratory coat.

Respiratory protection : If adequate local exhaust ventilation is not available or expo-

sure assessment demonstrates exposures outside the rec-

ommended guidelines, use respiratory protection.

Equipment should conform to BS EN 143

Filter type : Particulates type (P)

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Appearance : liquid Colour : white

off-white

Odour : No data available Odour Threshold : No data available

pH : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling

range

: No data available

Flash point : No data available

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Cefuroxime Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 2.5 28.09.2024 10846471-00007 Date of first issue: 06.09.2022

Evaporation rate : No data available

Flammability (solid, gas) : Not applicable

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower

flammability limit

No data available

Vapour pressure : No data available

Relative vapour density : No data available

Relative density : No data available

Density : No data available

Solubility(ies)

Water solubility
Partition coefficient: n-

octanol/water

: No data available

Not applicable

Auto-ignition temperature : No data available

Decomposition temperature : No data available

Viscosity

Viscosity, kinematic : No data available

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

9.2 Other information

Flammability (liquids) : No data available

Molecular weight : No data available

Particle size : Not applicable

SECTION 10: Stability and reactivity

10.1 Reactivity

Not classified as a reactivity hazard.

10.2 Chemical stability

Stable under normal conditions.

10.3 Possibility of hazardous reactions

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Cefuroxime Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 2.5 28.09.2024 10846471-00007 Date of first issue: 06.09.2022

Hazardous reactions : Can react with strong oxidizing agents.

10.4 Conditions to avoid

Conditions to avoid : None known.

10.5 Incompatible materials

Materials to avoid : Oxidizing agents

10.6 Hazardous decomposition products

No hazardous decomposition products are known.

SECTION 11: Toxicological information

11.1 Information on toxicological effects

Information on likely routes of : Inhalation

exposure Skin contact Ingestion

Eye contact

Acute toxicity

Not classified based on available information.

Components:

Cefuroxime:

Acute oral toxicity : LD50 (Rat): > 10,000 mg/kg

LD50 (Mouse): > 10,000 mg/kg

Acute toxicity (other routes of :

administration)

LD50 (Rat): > 4,000 mg/kg

Application Route: Intravenous

LD50 (Mouse): > 10,000 mg/kg Application Route: Intravenous

LD50 (Rabbit): > 1,500 mg/kg Application Route: Intravenous

LD50 (Dog): > 1,500 mg/kg Application Route: Intravenous

Skin corrosion/irritation

Not classified based on available information.

Serious eye damage/eye irritation

Not classified based on available information.

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Cefuroxime Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 2.5 28.09.2024 10846471-00007 Date of first issue: 06.09.2022

Respiratory sensitisation

May cause allergy or asthma symptoms or breathing difficulties if inhaled.

Components:

Cefuroxime:

Result : Sensitiser

Germ cell mutagenicity

Not classified based on available information.

Components:

Cefuroxime:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: Chromosomal aberration

Result: positive

Test Type: In vitro mammalian cell gene mutation test

Test system: mouse lymphoma cells

Result: negative

Genotoxicity in vivo : Test Type: Micronucleus test

Species: Mouse Result: negative

Carcinogenicity

Not classified based on available information.

Reproductive toxicity

Not classified based on available information.

Components:

Cefuroxime:

Effects on fertility : Test Type: Fertility

Species: Mouse

Application Route: Oral

Fertility: NOAEL: 6,400 mg/kg body weight

Symptoms: No adverse effects

Test Type: Fertility Species: Rabbit Application Route: Oral

Fertility: NOAEL: 400 mg/kg body weight

Symptoms: No adverse effects

STOT - single exposure

Not classified based on available information.

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Cefuroxime Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 2.5 28.09.2024 10846471-00007 Date of first issue: 06.09.2022

STOT - repeated exposure

Not classified based on available information.

Components:

Cefuroxime:

Assessment : May cause damage to organs through prolonged or repeated

exposure.

Repeated dose toxicity

Components:

Cefuroxime:

Species : Rat

NOAEL : 900 mg/kg Application Route : Subcutaneous

Exposure time : 3 M

Symptoms : No adverse effects

Species : Dog NOAEL : 400 mg/kg LOAEL : 1,600 mg/kg

Application Route : Oral Exposure time : 27 W Target Organs : Blood

Symptoms : Gastrointestinal disturbance

Species : Monkey
NOAEL : 450 mg/kg
Application Route : Subcutaneous

Exposure time : 1 M

Target Organs : Blood, Urinary tract

Remarks : May cause damage to organs.

Aspiration toxicity

Not classified based on available information.

Experience with human exposure

Components:

Cefuroxime:

General Information : Repeated contact may cause allergic reactions in very sus-

ceptible persons.

Inhalation : Symptoms: Nausea, Vomiting, Abdominal pain, vaginitis,

Headache, Dizziness, dry mouth, Fatigue, constipation, colitis

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Cefuroxime Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 2.5
 28.09.2024
 10846471-00007
 Date of first issue: 06.09.2022

SECTION 12: Ecological information

12.1 Toxicity

Components:

Cefuroxime:

Ecotoxicology Assessment

Acute aquatic toxicity : Toxic effects cannot be excluded

Chronic aquatic toxicity : Toxic effects cannot be excluded

12.2 Persistence and degradability

No data available

12.3 Bioaccumulative potential

Components:

Cefuroxime:

Partition coefficient: n-

octanol/water

: log Pow: -0.429

12.4 Mobility in soil

No data available

12.5 Results of PBT and vPvB assessment

Product:

Assessment : This substance/mixture contains no components considered

to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of

0.1% or higher.

12.6 Other adverse effects

Product:

Endocrine disrupting poten-

tial

This substance/mixture does not contain components considered to have endocrine disrupting properties for environment

according to UK REACH Article 57(f).

SECTION 13: Disposal considerations

13.1 Waste treatment methods

Product : Dispose of in accordance with local regulations.

According to the European Waste Catalogue, Waste Codes

are not product specific, but application specific.

Waste codes should be assigned by the user, preferably in

discussion with the waste disposal authorities.

Do not dispose of waste into sewer.

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Cefuroxime Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 2.5 28.09.2024 10846471-00007 Date of first issue: 06.09.2022

Contaminated packaging : Empty containers should be taken to an approved waste han-

dling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information

14.1 UN number

ADN : Not regulated as a dangerous good
ADR : Not regulated as a dangerous good
RID : Not regulated as a dangerous good
IMDG : Not regulated as a dangerous good
IATA : Not regulated as a dangerous good

14.2 UN proper shipping name

ADN : Not regulated as a dangerous good
ADR : Not regulated as a dangerous good
RID : Not regulated as a dangerous good
IMDG : Not regulated as a dangerous good
IATA : Not regulated as a dangerous good

14.3 Transport hazard class(es)

ADN : Not regulated as a dangerous good
ADR : Not regulated as a dangerous good
RID : Not regulated as a dangerous good
IMDG : Not regulated as a dangerous good
IATA : Not regulated as a dangerous good

14.4 Packing group

ADN : Not regulated as a dangerous good
ADR : Not regulated as a dangerous good
RID : Not regulated as a dangerous good
IMDG : Not regulated as a dangerous good
IATA (Cargo) : Not regulated as a dangerous good
IATA (Passenger) : Not regulated as a dangerous good

14.5 Environmental hazards

Not regulated as a dangerous good

14.6 Special precautions for user

Not applicable

14.7 Transport in bulk according to Annex II of Marpol and the IBC Code

Remarks : Not applicable for product as supplied.

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Cefuroxime Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 2.5
 28.09.2024
 10846471-00007
 Date of first issue: 06.09.2022

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mix-

Relevant EU provisions transposed through retained EU law

UK REACH List of restrictions (Annex 17) : Conditions of restriction for the fol-

lowing entries should be considered:

Number on list 3

Substance(s) or mixture(s) are listed here according to their appearance in the regulation, irrespective of their use/purpose or the conditions of the restriction. Please refer to the conditions in corresponding Regulation to determine whether an entry is applicable to the placing on the market or

not.

Not applicable

Not applicable

Not applicable

Not applicable

Not applicable

UK REACH Candidate list of substances of very high

concern (SVHC) for Authorisation

The Persistent Organic Pollutants Regulations (retained

Regulation (EU) 2019/1021 as amended for Great Brit-

ain)

Regulation (EC) on substances that deplete the ozone

layer

UK REACH List of substances subject to authorisation

(Annex XIV)

GB Export and import of hazardous chemicals - Prior

Informed Consent (PIC) Regulation

Control of Major Accident Hazards Regulations 2015 (COMAH)

Not applicable

Other regulations:

Take note of The Management of Health and Safety at Work Regulations 1999 (requirements relating to protection of young people at work contained in Regulation 19) and of Directive 94/33/EC on the protection of young people at work.

The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

Other information : Items where changes have been made to the previous version

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Cefuroxime Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 2.5
 28.09.2024
 10846471-00007
 Date of first issue: 06.09.2022

are highlighted in the body of this document by two vertical

lines.

Full text of H-Statements

H334 : May cause allergy or asthma symptoms or breathing difficul-

ties if inhaled.

H373 : May cause damage to organs through prolonged or repeated

exposure.

Full text of other abbreviations

Resp. Sens. : Respiratory sensitisation

STOT RE : Specific target organ toxicity - repeated exposure

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008: CMR - Carcinogen, Mutagen or Reproductive Toxicant: DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA -European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TECI -Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Further information

Sources of key data used to compile the Safety Data

Sheet

Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen-

cy, http://echa.europa.eu/

Classification of the mixture:

Classification procedure:

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Cefuroxime Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 2.5
 28.09.2024
 10846471-00007
 Date of first issue: 06.09.2022

Resp. Sens. 1 H334 Calculation method

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

GB / EN